Goldman Sachs Group Inc Avidity Biosciences, Inc. Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 874,747 shares of RNA stock, worth $36.1 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
874,747
Previous 544,051 60.78%
Holding current value
$36.1 Million
Previous $22.2 Million 80.78%
% of portfolio
0.01%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$37.21 - $48.14 $12.3 Million - $15.9 Million
330,696 Added 60.78%
874,747 $40.2 Million
Q2 2024

Aug 13, 2024
BUY
$22.73 - $40.85 $653,964 - $1.18 Million
28,771 Added 5.58%
544,051 $22.2 Million
Q1 2024

May 15, 2024
BUY
$9.16 - $25.52 $1.48 Million - $4.12 Million
161,635 Added 45.71%
515,280 $13.1 Million
Q4 2023

Feb 13, 2024
SELL
$4.87 - $9.37 $595,430 - $1.15 Million
-122,265 Reduced 25.69%
353,645 $3.2 Million
Q3 2023

May 14, 2024
BUY
$6.3 - $11.35 $770,269 - $1.39 Million
122,265 Added 34.57%
475,910 $3.04 Million
Q3 2023

Nov 14, 2023
SELL
$6.3 - $11.35 $503,527 - $907,148
-79,925 Reduced 14.38%
475,910 $3.04 Million
Q2 2023

May 14, 2024
SELL
$10.62 - $17.34 $4.86 Million - $7.94 Million
-457,640 Reduced 45.16%
555,835 $6.16 Million
Q2 2023

Aug 14, 2023
SELL
$10.62 - $17.34 $4.86 Million - $7.94 Million
-457,640 Reduced 45.16%
555,835 $6.16 Million
Q1 2023

May 14, 2024
SELL
$15.35 - $25.65 $1.62 Million - $2.7 Million
-105,312 Reduced 9.41%
1,013,475 $15.6 Million
Q1 2023

May 11, 2023
SELL
$15.35 - $25.65 $1.62 Million - $2.7 Million
-105,312 Reduced 9.41%
1,013,475 $15.6 Million
Q4 2022

May 14, 2024
BUY
$10.06 - $22.66 $5.03 Million - $11.3 Million
499,887 Added 80.77%
1,118,787 $24.8 Million
Q4 2022

Feb 13, 2023
BUY
$10.06 - $22.66 $5.03 Million - $11.3 Million
499,887 Added 80.77%
1,118,787 $24.8 Million
Q3 2022

May 14, 2024
BUY
$15.46 - $23.43 $6.73 Million - $10.2 Million
435,617 Added 237.67%
618,900 $10.1 Million
Q3 2022

Nov 10, 2022
BUY
$15.46 - $23.43 $6.73 Million - $10.2 Million
435,617 Added 237.67%
618,900 $10.1 Million
Q2 2022

May 14, 2024
SELL
$11.18 - $20.5 $1.9 Million - $3.49 Million
-170,362 Reduced 48.17%
183,283 $2.66 Million
Q2 2022

Aug 15, 2022
BUY
$11.18 - $20.5 $686,351 - $1.26 Million
61,391 Added 50.37%
183,283 $2.66 Million
Q1 2022

May 16, 2022
BUY
$14.2 - $23.78 $165,557 - $277,251
11,659 Added 10.58%
121,892 $2.25 Million
Q4 2021

Feb 14, 2022
SELL
$20.4 - $28.66 $4.78 Million - $6.71 Million
-234,246 Reduced 68.0%
110,233 $2.62 Million
Q3 2021

Nov 10, 2021
BUY
$18.16 - $25.21 $6.26 Million - $8.68 Million
344,479 New
344,479 $8.48 Million

Others Institutions Holding RNA

# of Institutions
256
Shares Held
107M
Call Options Held
224K
Put Options Held
161K
View Full List

About Avidity Biosciences, Inc.

RNA Quotes by TradingView
  • Ticker RNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,127,000
  • Market Cap $2.15B
  • Description
  • Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...
More about RNA
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email